Caladrius Biosciences (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Several other research analysts have also issued reports on the stock. Chardan Capital increased their price target on shares of Caladrius Biosciences from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Friday, March 23rd. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Caladrius Biosciences in a research note on Wednesday, March 14th.
Shares of Caladrius Biosciences stock opened at $5.08 on Friday. The stock has a market capitalization of $49.67, a P/E ratio of -2.85 and a beta of 1.17. Caladrius Biosciences has a 1 year low of $2.63 and a 1 year high of $6.35.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings results on Thursday, March 22nd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.30. analysts anticipate that Caladrius Biosciences will post -3.05 earnings per share for the current year.
An institutional investor recently raised its position in Caladrius Biosciences stock. Vanguard Group Inc. increased its holdings in Caladrius Biosciences (NASDAQ:CLBS) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,380 shares of the biotechnology company’s stock after acquiring an additional 4,163 shares during the quarter. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 5.75% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/caladrius-biosciences-clbs-stock-rating-lowered-by-zacks-investment-research.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.